HORSHAM, Pa.--()--Acurian, Inc., a leading, full-service provider of global patient enrollment and retention solutions, announced today that the first quarter was a new company record in terms of bookings, revenue, backlog, and new customers signed in a three-month period.
“Sponsors are looking for innovation and quality to drive research forward in a new era of drug and device development”
Bookings for the quarter were up 60% compared to Q1 2011, a significant achievement since the company had a full-year booking record in 2011. Revenue more than doubled as compared to Q1’11 and total backlog surpassed the company’s previous record. In addition, Acurian signed a record number of new customers in a single quarter, further expanding its footprint within the biopharmaceutical and medical device arena.
“Obviously, we are very pleased although not surprised by the company’s performance through March,” stated Rick Malcolm, Acurian’s CEO. “In 2011 we expanded the global capabilities of our core patient enrollment business, and invested in building up our retention and oncology services. It is clear from our first quarter performance that sponsors have responded positively.”
Malcolm believes that Acurian is well-positioned for continued growth as the sponsor community faces enormous pressure to replenish pipelines in the face of patent expirations and increased consumer demand for therapeutic options, while needing more data to satisfy regulatory authorities before and after product launch.
“Sponsors are looking for innovation and quality to drive research forward in a new era of drug and device development,” offered Malcolm. “Acurian has already established the technology, processes, people and experience that are required to meet customer expectations in that regard. This will only further strengthen our leadership position.”
Acurian is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening, and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites, time, or CRO change orders. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.